+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years - 100Years
All Genders
ID05798897

Phase 1 Study Evaluating MT-601 T Cell Therapy in Adults with Relapsed or Refractory Non-Hodgkin and Hodgkin Lymphoma

Led by Marker Therapeutics, Inc. · Updated on 2026-09-15

79

Participants Needed

7

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are conducting a Phase 1, multicenter, open-label clinical trial to study the safety and effectiveness of MT-601 in adults with relapsed or refractory non-Hodgkin lymphoma NHL or Hodgkin lymphoma HL. Participants include those who relapsed or had incomplete response after CD19-directed CAR T cell therapy, as well as those who are CAR T cell therapy naive due to ineligibility, refusal, or unavailability. The trial consists of two parts Dose Escalation and Dose Expansion phases, aiming to find a safe dose and then evaluate clinical efficacy. The investigational treatment, MT-601, consists of multi-tumor-associated antigen-specific CD4 and CD8 T cells administered at doses of 200 million or 400 million cells. The study begins with a Dose Escalation phase enrolling up to 50 participants to determine the recommended dose. Following this, the Dose Expansion phase will enroll up to 29 participants per disease-specific cohort to assess the clinical effects of MT-601 at the established dose. Participants will be involved in treatment and monitoring throughout the trial, including follow-up periods. Researchers will assess outcomes such as dose escalation safety after 28 days post-treatment and clinical responses like overall response rate, duration of response, and complete remission up to 12 months after treatment. Various health assessments, informed consent, and adherence to eligibility criteria are part of the study procedures. The trial is expected to complete by February 2028.

CONDITIONS

Brief Title

Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma

Research Team

J

Juan Vera, MD

P

Patricia Allison

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here